Calcitonin Receptor Inhibitors
1 drugsAbout Calcitonin Receptor
The Calcitonin Receptor (CTR) is a G protein-coupled receptor that binds calcitonin, a 32-amino acid peptide hormone involved in calcium homeostasis. Activation or inhibition of the receptor modulates cellular signaling pathways, influencing downstream effects depending on the tissue and context.
As a drug target, the calcitonin receptor has limited genetic validation, with no current evidence linking it to specific diseases. Further research is needed to strengthen the rationale for targeting this receptor in various disease contexts.
The calcitonin receptor has yielded one FDA-approved drug, calcitonin-salmon, a synthetic form of calcitonin. This drug, a small molecule, is marketed by PH HEALTH for niche applications.
Top Calcitonin Receptor Drugs
PH HEALTH is the only company with an approved drug targeting the calcitonin receptor.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market adoption.
Calcitonin Receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Calcitonin Receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing therapies.
Calcitonin Receptor Clinical Trials 4 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Calcitonin Receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Calcitonin Receptor Drug Approval Timeline (2008 - 2008)
The first and most recent drug approval for the calcitonin receptor was calcitonin-salmon in 2008.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Calcitonin Receptor. A trial counts if an approved drug acting on Calcitonin Receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.